As Speculation Mounts In Korea, Biosimilar Play Celltrion Still Seems Likely To Sell To Big Pharma
This article was originally published in PharmAsia News
Although Celltrion has raised eyebrows by saying it would consider the best interests of Korea’s pharmaceutical industry in a potential sale, most analysts still believe a multinational will win out. Speculation has heated up after a local report singled out AstraZeneca as a potential suitor.
You may also be interested in...
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma
SEOUL - Samsung Biologics, which hopes to establish itself as a global contract manufacturer in a long journey to become a global biopharmaceutical company, said it will eventually try to sell its biosimilars in the U.S. and EU markets rather than emerging markets
Korea's Samsung Electronics On Manhunt For Biosimilar Talent As Local Companies Keep Wary Eye On Competition
SEOUL - South Korea's leading biosimilar companies such as LG Life Sciences, Celltrion and others are increasingly wary of Samsung Electronics' ongoing talent search for research and development experts as the company prepares to make its debut in the blooming biosimilar business